Home-Based Transcranial Direct Current Stimulation for Depression: From Feasibility to Clinical Implementation
Pilloni et al., 2026. Neuropsychiatric Disease and Treatment
This review looks at where home-based tDCS for depression stands now that it has moved from early feasibility studies into clinical use.
- Efficacy: Randomized trials support home-based tDCS when it’s given with enough sessions, a structured protocol and supervision or adherence monitoring. The evidence points to about 28–42 sessions over 6–10 weeks.
- Real-world use: A study of 462 patients treated with Sooma tDCS in seven countries reported 54.9% response and 19.5% remission, with no serious adverse effects.
- Safety: One academic program delivered more than 30,000 supervised home sessions without skin lesions or serious adverse events linked to tDCS.
- Adherence: Easy-to-use devices, standardized training and remote monitoring help keep adherence high.
CONCLUSION: The evidence supports moving home-based tDCS from proof of concept into routine clinical care.